Every 8-K that Estrella Immunopharma, Inc. (ESLA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. (ESLA) reported receiving a notice from Nasdaq on September 1, 2026 that it no longer meets the Nasdaq Capital Market’s minimum $35,000,000 market value of listed securities requirement, after its MVLS stayed below that level for 30 consecutive business days.
Nasdaq also noted that the company does not meet the alternative standards for stockholders’ equity of at least $2,500,000 or net income of at least $500,000. ESLA has 180 calendar days, until March 1, 2027, to regain compliance by having MVLS at or above $35,000,000 for at least ten consecutive business days. Its common stock and warrants continue to trade on the Nasdaq Capital Market during this compliance period.
Estrella Immunopharma, Inc. (ESLA) reported that on August 17, 2026 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement, after trading below $1.00 for 30 consecutive business days from July 6 through August 14, 2026. The stock continues to trade on the Nasdaq Capital Market under “ESLA” while the company has 180 calendar days, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days, or longer at Nasdaq’s discretion. Estrella may use tools such as a reverse stock split, which would need to be completed at least ten business days before the compliance deadline, and could receive an additional 180-day period if it meets other Nasdaq listing standards. The company plans to monitor its share price and evaluate options, but states there is no assurance it will regain or maintain compliance.
Estrella Immunopharma, Inc. reported the results of its Combined 2025/2026 Annual Meeting of Stockholders held virtually on June 29, 2026. Stockholders voted on one proposal: ratification of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 43,034,228 shares of common stock outstanding and entitled to vote as of May 20, 2026, the record date. Holders of 30,351,608 shares were present or represented by proxy, representing approximately 70.5% of the eligible shares and establishing a quorum. Stockholders ratified the appointment of Macias Gini & O’Connell LLP with 30,351,203 votes for, 400 votes against, 5 abstentions and no broker non-votes.
Estrella Immunopharma, Inc. reported that on January 7, 2026 it received a notice from Nasdaq stating the company is not in compliance with Nasdaq Listing Rule 5620(a) because it has not held an annual meeting of shareholders within the required time period. The letter gives Estrella 45 calendar days to submit a plan to regain compliance.
The company plans to submit this compliance plan within the deadline and is currently planning to hold an annual shareholder meeting in April 2026. Estrella expects to discuss with Nasdaq whether this meeting will restore compliance or if additional actions will be required. The notice does not immediately affect the listing or trading of the company’s common stock or warrants on Nasdaq.
Estrella Immunopharma, Inc. entered into a securities purchase agreement for a registered direct offering and concurrent private placement that together generated approximately $8.0 million in gross proceeds. The company sold 4,063,290 shares of common stock and issued pre-funded warrants to purchase 1,000,000 shares of common stock at an exercise price of $0.00001 per share.
Each common share and each pre-funded warrant was paired with one and a half PIPE common warrants, with common units priced at $1.58 and pre-funded units at $1.57999. The PIPE common warrants are exercisable for up to 7,594,935 shares at $1.39 per share, are immediately exercisable, and expire five years after issuance, subject to a 4.99% or 9.99% ownership cap. The company plans to use net proceeds for general corporate purposes and working capital and agreed to register the resale of PIPE warrant shares under a future resale registration statement.
Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103. The company announced the milestone via a press release dated November 3, 2025, which is furnished as Exhibit 99.1 to this report.
Estrella Immunopharma, Inc. reported that Nasdaq has confirmed the company is back in full compliance with key continued listing rules. The first Nasdaq letter states Estrella has regained compliance with the minimum bid price requirement, after the company’s common stock maintained a closing bid of at least $1.00 per share for 10 consecutive business days from September 9, 2025 through September 22, 2025. Nasdaq now considers this bid-price matter closed.
The second Nasdaq letter confirms Estrella has also regained compliance with the minimum market value of listed securities requirement, as its market value of listed securities was at least $35,000,000 for 17 consecutive business days from August 28, 2025 through September 22, 2025. With both issues resolved, the company’s Nasdaq listing is no longer under these compliance deficiencies.
Estrella Immunopharma, Inc. reported a change in its leadership structure. On September 22, 2025, the Board of Directors appointed Jia Dengyao as a member of the Board, effective immediately. As of this report, he has not been appointed, and is not expected to be appointed, to any Board committees.
In connection with his appointment, the Company entered into an indemnification agreement with Mr. Jia on substantially similar terms as those provided to its other non-employee directors. This agreement commits Estrella Immunopharma to cover certain reasonable expenses, such as attorneys’ fees, court costs, and expert fees, that Mr. Jia may incur in actions or proceedings arising from his service as a director or in roles he undertakes at the Company’s request.